| _version_ |
1826265933812858880
|
| author |
Middleton, M
|
| author_facet |
Middleton, M
|
| author_sort |
Middleton, M
|
| collection |
OXFORD
|
| description |
|
| first_indexed |
2024-03-06T20:31:21Z
|
| format |
Journal article
|
| id |
oxford-uuid:31259d98-108d-4b60-8d12-060c7eb96e1a
|
| institution |
University of Oxford
|
| language |
English
|
| last_indexed |
2024-03-06T20:31:21Z
|
| publishDate |
2018
|
| publisher |
Elsevier
|
| record_format |
dspace
|
| spelling |
oxford-uuid:31259d98-108d-4b60-8d12-060c7eb96e1a2022-03-26T13:06:03ZLong-term survival with anti-PD-1-based immunotherapy, but what is the best approach?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:31259d98-108d-4b60-8d12-060c7eb96e1aEnglishSymplectic Elements at OxfordElsevier2018Middleton, M
|
| spellingShingle |
Middleton, M
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title_full |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title_fullStr |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title_full_unstemmed |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title_short |
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
|
| title_sort |
long term survival with anti pd 1 based immunotherapy but what is the best approach
|
| work_keys_str_mv |
AT middletonm longtermsurvivalwithantipd1basedimmunotherapybutwhatisthebestapproach
|